Australian biotechs significantly outperforming ASX and Nasdaq
24 October, 2012 by Tim DeanThe Australian life science index is known for its volatility, but over the past decade it has outperformed the All Ordinaries and the Nasdaq by considerable margins.
Biota cleared to merge with Nabi
23 October, 2012 by Dylan Bushell-EmblingBiota Holdings (ASX:BTA) has been cleared to merge with Nabi Biopharmaceuticals after shareholders in both companies approved the deal.
Latest journal features AusBiotech 2012, tech transfer and more…
23 October, 2012 by AusBiotechAusBiotech is pleased to announce that the bumper special edition of AusBiotech’s journal, Australasian Biotechnology, is now published, featuring a sneak peek at next week’s industry conference of the year, AusBiotech 2012, as well as a feature on tech transfer and biotechnology in Asia.
Test strip earnings boost UBI revenue
22 October, 2012 by Dylan Bushell-EmblingUniversal Biosensors (ASX:UBI) boosted its Q3 revenue by 50% and slashed its cash outflow, thanks to contributions from its two coagulation test strip partnerships.
Bioniche launches canine cancer product in NA
19 October, 2012 by Dylan Bushell-EmblingBioniche Life Sciences (ASX:BNC) has launched its first canine cancer product, Immunocidin, in the US and Canadian markets.
Bluechiip enters sample tracking tie-up
19 October, 2012 by Dylan Bushell-EmblingBluechiip (ASX:BCT) has partnered with Swiss laboratory systems developer Inpeco, agreeing to explore jointly developing Inpeco products with integrated Bluechiip tracking chips.
Allied Healthcare's CardioCel used in first non-trial procedure
18 October, 2012 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) has reached a milestone with its CardioCel cardiovascular patch product, announcing its first surgical use outside of clinical trials.
State finalists for Student Excellence Awards announced
18 October, 2012 by AusBiotechThe state finalists of the 2012 AusBiotech/GSK Student Excellence Awards have been announced. Sixteen promising research students competed for the chance to represent their state, and the six state finalists will now compete at the AusBiotech national conference to win a $7,000 travel grant.
Bionomics presenting early Alpha 7 data
17 October, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) is presenting details of its its Alpha 7 program targeting Alzheimers and other neurodegenerative conditions at Neuroscience 2012, as it embarks on the hunt for a licensing deal.
STA licenses treatment for cachexia-anorexia
17 October, 2012 by Dylan Bushell-EmblingSpecialised Therapeutics Australia (STA) has negotiated commercialisation rights for a new drug to treat cachexia-anorexia, a serious condition linked with advanced cancers.
CSL to conduct another $900m buyback
17 October, 2012 by Dylan Bushell-EmblingCSL (ASX:CSL) has announced another up to $900 million share buyback, and has affirmed its guidance for FY13.
Clinuvel data show SCENESSE accelerates repigmentation
16 October, 2012 by Dylan Bushell-EmblingThe first published data from Clinuvel's (ASX:CUV) trial of SCENESSE in patients with skin condition vitiligo indicate that the treatment can help accelerate repigmentation of the skin.
Biotron hepatitis treatment looks promising
16 October, 2012 by Dylan Bushell-EmblingData from a trial of Biotron's (ASX:BIT) novel hepatitis C (HCV) treatment candidate shows that all patients treated with the highest dose had undetectable levels of the virus at 48-week follow up.
Feds announce another review on patents
16 October, 2012 by AusBiotechThe Federal Government has announced the commission of an expert panel to review the “appropriateness of the extension arrangements for pharmaceutical patents.” This review is part of a broad range of measures the Government is undertaking to scrutinise the Australian patent system.
Promising results from Prima BioMed ovarian cancer trial
15 October, 2012 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has reported promising interim results from a phase II trial of CVac, its prospective ovarian cancer vaccine.
